| Abstrakt: |
BEAVERTON, Ore., Nov. 2, 2021 /PRNewswire/ -- Wilms' tumor is the most common form of kidney cancer in pediatrics, affecting approximately 500 children per year in North America. "Children with Wilms' tumors driven by a gene called MYCN, particularly those with anaplastic (or unfavorable) histology, tend to fare more poorly than those without MYCN abnormalities. MYCN has been notoriously challenging to block," said Michael Ortiz, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center, and co-author on the study. "Our rigorous investigation used a focused drug screen and found that BRD4 inhibition was a promising novel approach to target MYCN driven Wilms' tumors. These findings were then validated in a large cohort of cell line and patient derived xenograft Wilms tumor models with encouraging results worthy of consideration in future clinical studies." [ABSTRACT FROM PUBLISHER] |
